StockNews.com Upgrades uniQure (NASDAQ:QURE) to Sell

uniQure (NASDAQ:QURE) was upgraded by StockNews.com to a “sell” rating in a research note issued on Wednesday.

A number of other research firms have also recently weighed in on QURE. Leerink Partners lifted their target price on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. Cantor Fitzgerald lifted their target price on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $40.00.

uniQure Stock Performance

NASDAQ:QURE traded up $0.22 during mid-day trading on Wednesday, hitting $16.13. 959,066 shares of the company traded hands, compared to its average volume of 1,093,868. uniQure has a one year low of $3.73 and a one year high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market cap of $786.18 million, a price-to-earnings ratio of -3.25 and a beta of 0.39. The stock’s fifty day moving average price is $14.29 and its 200-day moving average price is $9.09.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Research analysts anticipate that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of QURE. abrdn plc lifted its position in shares of uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the last quarter. Franklin Resources Inc. purchased a new position in uniQure in the 3rd quarter worth about $7,360,000. Point72 Asset Management L.P. lifted its holdings in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after buying an additional 752,889 shares in the last quarter. FMR LLC boosted its position in uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after buying an additional 346,274 shares during the period. Finally, Privium Fund Management B.V. grew its stake in uniQure by 16.3% in the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after acquiring an additional 104,500 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.